Clinical trial
A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Antitumor Efficacy of LNF2105 in Patients With Advanced Solid Tumors.
NCT07661797 is registered in ClinicalTrials.gov with Shandong New Time Pharmaceutical Co., LTD as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Antitumor Efficacy of LNF2105 in Patients With Advanced Solid Tumors.
- Lead sponsor
- Shandong New Time Pharmaceutical Co., LTD
- Phase
- Phase 1
- Overall status
- Not yet recruiting
- Start date
- June 30, 2026
- Completion date
- August 31, 2028
- Enrollment
- 294 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
patients with advanced solid tumors